Cargando…
Practical considerations in the use of regorafenib in metastatic colorectal cancer
Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, reg...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607787/ https://www.ncbi.nlm.nih.gov/pubmed/33193826 http://dx.doi.org/10.1177/1758835920956862 |
_version_ | 1783604712946270208 |
---|---|
author | Loupakis, Fotios Antonuzzo, Lorenzo Bachet, Jean-Baptiste Kuan, Feng-Che Macarulla, Teresa Pietrantonio, Filippo Xu, Rui-Hua Taniguchi, Hiroya Winder, Thomas Yuki, Satoshi Zeng, Shan Bekaii-Saab, Tanios |
author_facet | Loupakis, Fotios Antonuzzo, Lorenzo Bachet, Jean-Baptiste Kuan, Feng-Che Macarulla, Teresa Pietrantonio, Filippo Xu, Rui-Hua Taniguchi, Hiroya Winder, Thomas Yuki, Satoshi Zeng, Shan Bekaii-Saab, Tanios |
author_sort | Loupakis, Fotios |
collection | PubMed |
description | Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician–patient communication points to facilitate shared decision-making. |
format | Online Article Text |
id | pubmed-7607787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-76077872020-11-13 Practical considerations in the use of regorafenib in metastatic colorectal cancer Loupakis, Fotios Antonuzzo, Lorenzo Bachet, Jean-Baptiste Kuan, Feng-Che Macarulla, Teresa Pietrantonio, Filippo Xu, Rui-Hua Taniguchi, Hiroya Winder, Thomas Yuki, Satoshi Zeng, Shan Bekaii-Saab, Tanios Ther Adv Med Oncol Review Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician–patient communication points to facilitate shared decision-making. SAGE Publications 2020-10-31 /pmc/articles/PMC7607787/ /pubmed/33193826 http://dx.doi.org/10.1177/1758835920956862 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Loupakis, Fotios Antonuzzo, Lorenzo Bachet, Jean-Baptiste Kuan, Feng-Che Macarulla, Teresa Pietrantonio, Filippo Xu, Rui-Hua Taniguchi, Hiroya Winder, Thomas Yuki, Satoshi Zeng, Shan Bekaii-Saab, Tanios Practical considerations in the use of regorafenib in metastatic colorectal cancer |
title | Practical considerations in the use of regorafenib in metastatic colorectal cancer |
title_full | Practical considerations in the use of regorafenib in metastatic colorectal cancer |
title_fullStr | Practical considerations in the use of regorafenib in metastatic colorectal cancer |
title_full_unstemmed | Practical considerations in the use of regorafenib in metastatic colorectal cancer |
title_short | Practical considerations in the use of regorafenib in metastatic colorectal cancer |
title_sort | practical considerations in the use of regorafenib in metastatic colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607787/ https://www.ncbi.nlm.nih.gov/pubmed/33193826 http://dx.doi.org/10.1177/1758835920956862 |
work_keys_str_mv | AT loupakisfotios practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT antonuzzolorenzo practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT bachetjeanbaptiste practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT kuanfengche practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT macarullateresa practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT pietrantoniofilippo practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT xuruihua practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT taniguchihiroya practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT winderthomas practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT yukisatoshi practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT zengshan practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer AT bekaiisaabtanios practicalconsiderationsintheuseofregorafenibinmetastaticcolorectalcancer |